This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Journals
    Journal
    30/04/19

    Venetoclax in the treatment of chronic lymphocytic leukemia

    Areas covered: This article reviews the chemical structure, mechanisms of action, pharmacokinetic, and the clinical applications of venetoclax in monotherapy and in combined treatment of CLL.

    • Source: Expert Opinion on Drug Metabolism & Toxicology
    Journals
    Journal
    02/04/19

    Chronic lymphocytic leukaemia: the role of T cells in a B cell disease

    Chronic lymphocytic leukaemia (CLL) has long been thought to be an immunosuppressive disease and abnormalities in T-cell subset distribution and function have been observed in many studies. However, the role of T cells (if any)...

    • Source: British Journal of Haematology
    Journals
    Journal
    01/11/19

    Chronic lymphocytic leukaemia: from genetics to treatment.

    Chronic lymphocytic leukaemia (CLL), the most frequent type of leukaemia in adults, is a lymphoproliferative disorder that is characterized by the expansion of monoclonal, mature CD5+CD23+ B cells in the peripheral blood...

    • Source: Nature Reviews Clinical Oncology
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    04/09/23

    Calquence approved in China for chronic lymphocytic leukaemia

    AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in China for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy

    Journals
    Journal
    15/02/19

    Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.

    Venetoclax is a BCL2 inhibitor with activity in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). We conducted a multi?centre retrospective analysis of 105 R/R CLL patients who received venetoclax...

    • Source: British Journal of Haematology
    Journals
    Journal
    10/09/19

    Role of microRNAs in chronic lymphocytic leukemia pathogenesis.

    MicroRNAs (miRNAs) are a group of small endogenous non-coding RNAs involved in many cancers and various cellular processes such as cellular growth, DNA methylation, apoptosis, and differentiation.

    • Source: Current Medicinal Chemistry
    Guidelines
    Guideline
    01/09/24

    ESMO interim update on new targeted therapies in the first-line and at relapse of CLL

    This ESMO interim update outlines new targeted therapies for chronic lymphocytic leukaemia (CLL), including time-limited ibrutinib–venetoclax and zanubrutinib for first-line and relapsed cases. It also highlights MRD-driven treatment strategies and evolving options for later-line therapies based on prior regimens.

    • Source: European Society for Medical Oncology (ESMO)
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    22/11/19

    FDA approves Calquence to treat chronic lymphocytic leukaemia or small lymphocytic lymphoma.- AstraZeneca.

    AstraZeneca announced that the FDA has approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    31/07/14

    Arzerra trial for CLL meets endpoint in interim analysis - GSK/Genmab

    GlaxoSmithKline and Genmab have announced that an Independent Data Monitoring Committee (IDMC) interim analysis of a Phase III study, PROLONG...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    16/06/19

    Phase III ASCEND trial showed Calquence prolonged the time patients live without disease progression in chronic lymphocytic leukaemia (CLL)

    AstraZeneca announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association (EHA)...

    See more